COVID trial


VB10.COV2 VB-D-01

For information about the trial and participation – Information in Norwegian:

An open label, Phase 1/2, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). Three dose levels will be tested. IM administrations 21 days apart.

The trial is open for enrollment at sites in Norway. Identifier: NCT05069623